Dow Up1.06% Nasdaq Up1.74%

Halozyme Therapeutics, Inc. (HALO)

9.04 Down 0.11(1.20%) 12:16PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road
San Diego, CA 92121
United States - Map
Phone: 858-794-8889
Fax: 858-704-8311

Index Membership:N/A
Full Time Employees:170

Business Summary 

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Halozyme Therapeutics, Inc.

Corporate Governance 
Halozyme Therapeutics, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 10; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. David A. Ramsay MBA, 49
Chief Financial Officer, Principal Accounting Officer and VP
Ms. Jean I. Liu J.D., M.S., 45
VP, Gen. Counsel and Sec.
Mr. James P. Shaffer , 47
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., 51
Chief Exec. Officer, Pres and Director
Mr. William J. Fallon , 57
VP of Manufacturing and Operations
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders